We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · July 02, 2020

Applying Guidelines for Use of SGLT2is and GLP1-RAs as First-line Monotherapy or Add-on Therapy in Type 2 Diabetes

Diabetes Care


Additional Info

Diabetes Care
Prescribing Paradigm Shift? Applying the 2019 European Society of Cardiology–Led Guidelines on Diabetes, Prediabetes, and Cardiovascular Disease to Assess Eligibility for Sodium-Glucose Cotransporter 2 Inhibitors or Glucagon-Like Peptide 1 Receptor Agonists as First-Line Monotherapy (or Add-on to Metformin Monotherapy) in Type 2 Diabetes in Scotland
Diabetes Care 2020 Jun 24;[EPub Ahead of Print], TM Caparrotta, LAK Blackbourn, SJ McGurnaghan, J Chalmers, R Lindsay, R McCrimmon, J McKnight, S Wild, JR Petrie, S Philip, PM McKeigue, DJ Webb, N Sattar, HM Colhoun

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading